Home  |  Contact

Cellosaurus C2ABR (CVCL_IW75)

[Text version]

Cell line name C2ABR
Synonyms Control 2 Australia BRisbane
Accession CVCL_IW75
Resource Identification Initiative To cite this cell line use: C2ABR (RRID:CVCL_IW75)
Comments From: Queensland Institute of Medical Research; Brisbane; Australia.
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Derived from sampling site: Peripheral blood.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 69Y
Category Transformed cell line

PubMed=6504056; DOI=10.1016/0027-5107(84)90149-0
Chen P., Imray F.P., Kidson C.
Gene dosage and complementation analysis of ataxia telangiectasia lymphoblastoid cell lines assayed by induced chromosome aberrations.
Mutat. Res. 129:165-172(1984)

PubMed=2836804; DOI=10.1093/nar/16.9.3919
Singh S.P., Mohamed R., Salmond C., Lavin M.F.
Reduced DNA topoisomerase II activity in ataxia-telangiectasia cells.
Nucleic Acids Res. 16:3919-3929(1988)

PubMed=1944384; DOI=10.1016/0921-8734(91)90029-B
Chen P., Kidson C., Lavin M.F.
Heterogeneity in Alzheimer's disease: evidence from cellular radiosensitivity and complementation of this phenotype.
Mutat. Res. 256:21-27(1991)

PubMed=9150358; DOI=10.1038/sj.onc.1201037
Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., Ramsay J., Gatti R.A., Lavin M.F.
Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms.
Oncogene 14:1911-1921(1997)

PubMed=11080496; DOI=10.1074/jbc.M006190200
Gueven N., Keating K.E., Chen P., Fukao T., Khanna K.K., Watters D., Rodemann P.H., Lavin M.F.
Epidermal growth factor sensitizes cells to ionizing radiation by down-regulating protein mutated in ataxia-telangiectasia.
J. Biol. Chem. 276:8884-8891(2001)

PubMed=17347666; DOI=10.1038/sj.cdd.4402116
Gueven N., Becherel O.J., Howe O., Chen P., Haince J.-F., Ouellet M.-E., Poirier G.G., Waterhouse N., Fusser M., Epe B., de Murcia J.M., de Murcia G., McGowan C.H., Parton R., Mothersill C., Grattan-Smith P., Lavin M.F.
A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance.
Cell Death Differ. 14:1149-1161(2007)

PubMed=17562789; DOI=10.1083/jcb.200701042
Suraweera A., Becherel O.J., Chen P., Rundle N., Woods R., Nakamura J., Gatei M., Criscuolo C., Filla A., Chessa L., Fusser M., Epe B., Gueven N., Lavin M.F.
Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage.
J. Cell Biol. 177:969-979(2007)

PubMed=19643912; DOI=10.1093/hmg/ddp359
Harris J.L., Jakob B., Taucher-Scholz G., Dianov G.L., Becherel O.J., Lavin M.F.
Aprataxin, poly-ADP ribose polymerase 1 (PARP-1) and apurinic endonuclease 1 (APE1) function together to protect the genome against oxidative damage.
Hum. Mol. Genet. 18:4102-4117(2009)

Other Wikidata; Q54808116
Entry history
Entry creation03-Mar-2017
Last entry updated02-Jul-2020
Version number4